NAD+ IV Therapy for Depression and Anxiety: The Evidence
Clinics market NAD+ IV drips for depression, anxiety, and mood. An honest look at the mitochondrial rationale, the weak human evidence, and why to be cautious.
Updated
6 min read · 11 sources
On this page
If you search for help with depression or anxiety, you'll eventually find a wellness clinic offering an intravenous NAD+ drip as a "natural reset" for your mood — sometimes pitched as a way to "rebalance brain chemistry" or "restore mental clarity" without medication. The marketing is confident, the testimonials are glowing, and the mechanism, on the surface, sounds scientific: your brain runs on cellular energy, NAD+ powers that energy, so topping it up should lift your mood.
Mental health is exactly the area where that kind of confident, mechanism-flavored pitch deserves the most scrutiny — because depression and anxiety are serious, sometimes dangerous conditions, and because people in distress are especially vulnerable to spending money on hope. So this page lays out, honestly, why NAD+ is even proposed for mood, what the human evidence can establish (limited, indirect findings rather than proven antidepressant efficacy), and why an IV drip should not be mistaken for treatment.
Featured partner
CoreAge Rx
From $93/mo
Check availabilityRead our reviewAffiliate link. We may earn a commission at no extra cost to you.
Affiliate partner
System Labs
Compounded NAD+ & longevity telehealth
See System LabsIf you are in crisis or having thoughts of harming yourself, please reach out now — in the US, call or text 988 (the Suicide & Crisis Lifeline). This article is about evaluating a marketed therapy, not a substitute for care.
Why NAD+ is even proposed for mood
NAD+ helps cells process energy and supports enzymes involved in DNA repair and cellular regulation 1. Human tissue research also links aging and metabolic stress with changes in NAD+ availability 2. Those observations explain interest in mood research, but neither a cellular role nor an age association demonstrates that low NAD+ causes a person’s depression or that supplementation treats it.
What gives the mood pitch a sheen of credibility is a genuine and growing line of research linking mitochondrial dysfunction to depression. People with major and bipolar depression show measurable alterations in mitochondrial DNA — oxidation, methylation, and copy-number changes 3 — and patients in acute bipolar episodes show reduced mitochondrial respiratory capacity, leading some researchers to frame mood disorders partly as state-dependent "mitochondrial" conditions 4. There's even a small human signal tying NAD+ metabolism specifically to mood: a 2025 preliminary study found that serum nudifloramide concentrations differed across treated patients with persistent depression, patients in remission, and healthy controls in a cross-sectional study 5.
Bipolar depression needs its own treatment decisions. Our NAD+ and bipolar disorder guide explains why mitochondrial findings should not be transferred into a supplement recommendation.
The marketed rationale
Mood disorders ↔ mitochondria
Real correlation: altered mitochondrial DNA and respiratory capacity in depression
Mitochondria ↔ NAD+
Plausible: NAD+ fuels mitochondrial energy; an NAD+ metabolite tracks treatment response
Raise NAD+ → better mood
NOT proven — the long-COVID NR trial did not establish a mood benefit
So the chain the clinics draw — low cellular energy → mitochondrial dysfunction → depression → fix it by raising NAD+ — has real scientific touchpoints. The problem is that every one of those touchpoints is a correlation or a mechanism, and none of them is evidence that giving someone NAD+ actually treats their depression or anxiety.
What the human evidence actually shows
Here is the honest core of this page: NAD+ IV therapy has no established controlled evidence of efficacy for depression or anxiety. Related oral compounds have been studied in other patient groups, but those studies do not answer whether an NAD+ drip treats a primary mood or anxiety disorder.
The most relevant trial gave oral nicotinamide riboside (NR), a well-studied NAD+ precursor, at 2,000 mg/day in a double-blind, placebo-controlled study, and it measured anxiety and depression symptoms among its outcomes 6. The result: no significant between-group difference in symptoms of anxiety (p = 0.84) or depression (p = 0.20) versus placebo 6. Participants did report some within-group improvement while taking NR, but that uncontrolled comparison is exactly the kind of signal that placebo and natural fluctuation produce — which is why the placebo-controlled comparison is the one that counts, and it was null. (That trial was in long-COVID patients rather than primary depression, so it isn't the final word — but it did not establish a mood benefit in the population actually studied.)
The NR study enrolled 58 people with long COVID and excluded major active or unstable psychiatric illness. Mood was a secondary outcome, and dropout was substantial. A non-significant result does not prove that a treatment can never help; it means this trial did not demonstrate that it did 6.
There is also older, indirect NADH evidence: a placebo-controlled ME/CFS trial reported an anxiety signal but no improvement in most clinical measures or overall function 10. It tested a different molecule and condition, not IV NAD+ for an anxiety disorder. The ME/CFS review explains those limitations.
For the IV route specifically — the one the mood clinics actually sell — the evidence is thinner still. A 2019 human IV NAD+ pilot measured the metabolome during a 6-hour infusion and found no significant plasma NAD+ increase in the first two hours, followed by an increase at six hours; it tested no psychiatric outcome at all 7. The pharmacokinetic findings do not establish an antidepressant or anti-anxiety effect. Controlled efficacy for IV NAD+ in primary depression or anxiety remains unestablished. We cover that route's evidence and cost in detail in our NAD+ IV therapy evidence guide.
Strength of evidence
- Mitochondrial dysfunction ↔ depressionModerate evidence
Human studies show mtDNA and respiratory-capacity differences — a correlation, not a treatment.
- Oral NAD+ precursors → mood symptomsWeak evidence
Placebo-controlled NR trial: no significant between-group benefit (anxiety p=0.84, depression p=0.20).
- IV NAD+ → depression / anxietyNone evidence
No established controlled evidence of a depression benefit; the 2019 pilot measured pharmacokinetics, not mood.
- Raised NAD+ → felt benefitWeak evidence
Biomarker rises without reliable improvement in the conditions actually studied.
This fits a pattern that runs through the entire NAD+ field: raising the NAD+ biomarker reliably is not the same as improving how people feel or function. When NR raised NAD+ in older adults with mild cognitive impairment, cognition was unchanged 8; a systematic review and meta-analysis of NAD+ precursors on metabolic-syndrome parameters found benefits limited and inconsistent despite reliably raised NAD+ 9. If the biomarker moves but the outcomes don't in the conditions that have been studied, an IV drip marketed for mood — with no mood trials behind it — cannot honestly claim to work. We unpack this "biomarker is not benefit" problem in our pillar guide to NAD+ therapy evidence and in does NAD+ actually boost energy.
Why the testimonials are weak evidence
Mood is one of the most placebo-responsive outcomes in all of medicine. Depression and anxiety fluctuate naturally, often improve with time, attention, and structure, and respond strongly to expectation. An expensive, ritualized, hours-long infusion delivered by attentive staff in a calming clinic is practically engineered to produce a felt lift — regardless of what's in the bag. That's not a knock on the people who feel better; it's the entire reason placebo-controlled trials exist, and it's why a glowing testimonial can't substitute for a controlled comparison. The long-COVID NR comparison did not establish a mood benefit over placebo 6.
This is the same caution we raise about NAD+ drips marketed for addiction recovery, another high-stakes psychiatric arena where the pitch outruns the proof.
What actually has evidence — and don't trade it away
This is the most important section. Depression and anxiety have treatments backed by large, controlled trials and decades of clinical experience: psychotherapy (especially cognitive behavioral therapy), antidepressant and anti-anxiety medications, and, for treatment-resistant cases, options like newer rapid-acting agents and brain-stimulation therapies. Treatment choice depends on diagnosis, severity, medical history, preferences and prior response. NIMH describes psychotherapy, medication and brain-stimulation options, including their different roles in depression care 11. Costs and access vary.
The real danger of the NAD+-for-mood pitch is opportunity cost: someone in genuine distress spends hundreds or thousands of dollars on an unproven drip instead of seeking care that is known to help — or worse, delays treatment for a worsening condition. At best, NAD+ IV therapy is an expensive, unproven add-on with no controlled evidence for mood. It is not a treatment for depression or anxiety, and any clinic implying otherwise is overselling.
If you're drawn to NAD+, understand the whole picture first and talk to a mental-health professional about your symptoms. Start with our NAD+ therapy evidence pillar, see the route reality and pricing in our NAD+ IV therapy evidence guide, review the side effects before any infusion, and see how products and providers compare on our NAD+ rankings hub. For your mood itself, the evidence-based first step is a clinician — not a drip.
Frequently asked questions
Does NAD+ IV therapy treat depression or anxiety?
Controlled evidence has not established that it does. A 58-person NR trial in long COVID found no significant mood advantage over placebo, but it was not a trial of IV NAD+ or primary depression. It also cannot prove that a treatment never helps. The evidence does not justify replacing established mental-health care with a drip.
Why do clinics say NAD+ helps mood if it's not proven?
Because there's a real research link between mitochondrial dysfunction and depression, and NAD+ powers mitochondrial energy — so the mechanism sounds plausible. But those are correlations and mechanisms, not proof that giving someone NAD+ treats their depression. Marketing leans on the plausible biology and on testimonials, which are weak evidence for a highly placebo-responsive outcome like mood.
Is there any human evidence for NAD+ and mood?
There are indirect findings: mitochondrial and metabolite associations, a long-COVID NR trial with no significant mood benefit over placebo, and an older ME/CFS NADH trial with a limited anxiety signal. These involve different populations and compounds and do not establish IV NAD+ as a treatment for a mood or anxiety disorder.
What actually works for depression and anxiety?
Treatments backed by large controlled trials include psychotherapy such as cognitive behavioral therapy, antidepressant and anti-anxiety medications, and, for treatment-resistant cases, newer rapid-acting agents and brain-stimulation therapies. A clinician can help select care for the diagnosis, severity, history and preferences; cost and access vary. An unproven NAD+ drip should never replace seeking that care. If you are in crisis, in the US call or text 988.
References
- Covarrubias AJ, Perrone R, Grozio A, Verdin E (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. https://pubmed.ncbi.nlm.nih.gov/33353981/
- Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ (2012). Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. https://pubmed.ncbi.nlm.nih.gov/22848760/
- Ceylan D, Karacicek B, Tufekci KU, et al. (2023). Mitochondrial DNA oxidation, methylation, and copy number alterations in major and bipolar depression. Frontiers in Psychiatry. https://pubmed.ncbi.nlm.nih.gov/38161720/
- Giménez-Palomo A, Gomes-da-Costa S, Dodd S, et al. (2024). Reduced mitochondrial respiratory capacity in patients with acute episodes of bipolar disorder: Could bipolar disorder be a state-dependent mitochondrial disease?. Acta Psychiatrica Scandinavica. https://pubmed.ncbi.nlm.nih.gov/38030136/
- Lee S, Kim D, Kang HG, Lee J (2025). Alterations in serum nudifloramide associated with response to diverse pharmacological treatments in major depressive disorder: a preliminary study. Metabolic Brain Disease. https://pubmed.ncbi.nlm.nih.gov/41065915/
- Wu CY, et al. (2025). Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. EClinicalMedicine. https://pubmed.ncbi.nlm.nih.gov/41357333/
- Grant R, Berg J, Mestayer R, et al. (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience. https://pubmed.ncbi.nlm.nih.gov/31572171/
- Orr ME, Kotkowski E, Ramirez P, et al. (2024). A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience. https://pubmed.ncbi.nlm.nih.gov/37994989/
- Oliveira-Cruz A, et al. (2024). Effects of Supplementation with NAD+ Precursors on Metabolic Syndrome Parameters: A Systematic Review and Meta-Analysis. Hormone and Metabolic Research. https://pubmed.ncbi.nlm.nih.gov/39111741/
- Alegre J, Rosés JM, Javierre C, et al. (2010). Nicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndrome. Revista Clínica Española. https://pubmed.ncbi.nlm.nih.gov/20447621/
- National Institute of Mental Health (2024). Depression. NIMH. https://www.nimh.nih.gov/health/publications/depression
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Related reading
NAD+ IV Therapy for Addiction Recovery: What the Evidence Shows
Detox clinics market NAD+ IV drips for withdrawal and cravings. An honest look at the claimed mechanism, the very weak human evidence, and the cost.
ReadNAD+ for Weight Loss: What the Human Evidence Actually Shows
NMN reversed diet-induced obesity in mice — but in humans, the key NAD+ trial left body weight unchanged. An honest look at NAD+ for weight loss.
ReadNAD+ for Arthritis: What the Human Evidence Actually Tests
What arthritis studies actually show: a niacinamide osteoarthritis pilot, rheumatoid arthritis cell research and a 2026 NAD+ IV case report.
ReadNAD+ and NMN for Hair Growth: What the Studies Tested
Hair-growth research on NMN, NAD+ and topical blends: what mice, follicle cells and human studies do—and do not—show about regrowth.
ReadNAD+ for Brain Fog: What Human Cognition Trials Show
Does NAD+ help brain fog? Compare oral NR cognition trials with claims for injections, and distinguish brain fog from MCI and dementia.
ReadNAD+ IV Therapy: Evidence, Benefits & What It Costs
What the human evidence actually shows for NAD+ IV therapy, the benefits clinics promise vs. what's proven, and a realistic look at the cost.
Read